TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35604806

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine + Azithromycin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 35605011

Group type: EXPERIMENTAL
Intervention: Plasma antibodies from SFV-infected individuals
Number of subjects: 29

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 29
Study: 35605051

Group type: EXPERIMENTAL
Intervention: Videoconferencing while expressing human milk
Number of subjects: 0
Study: 35605184

Group type: EXPERIMENTAL
Intervention: CD19.22.BBζ
Number of subjects: 20
Study: 35605238

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (n=189)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (n=120)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (unvaccinated)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (vaccinated)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort with PASC
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Exploratory studies
Number of subjects: 309
Study: 35605481

Group type: EXPERIMENTAL
Intervention: Cenobamate (12.5, 25, 50, 100, 150, 200 mg/day, target dose 200 mg/day, with further increases to 400 mg/day by 50 mg/day increments every other week)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 240
Study: 35605659

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 10933

Group type: COMPARATOR
Intervention: Full reporting database
Number of subjects: 10933
Study: 35606228

Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy (DR)
Number of subjects: 3442
Study: 35606551

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 159
Study: 35606646

Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medication prescribing (PIP) detected by a computer algorithm
Number of subjects: 1525
Study: 35606704

Group type: EXPERIMENTAL
Intervention: Gluten Free Diet (GFD)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (Healthy Children)
Number of subjects: 138
Study: 35606731

Group type: EXPERIMENTAL
Intervention: ClinTouch DAWN-P app for daily EPDS assessments
Number of subjects: 23
Study: 35606736

Group type: EXPERIMENTAL
Intervention: Interactive text messages and electronic resources provided to participants.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electronic educational resources, interactive text messages, and faxed materials to PCPs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic resources only.
Number of subjects: 0
Study: 35606839

Group type: EXPERIMENTAL
Intervention: Swept-source optical coherence tomographer (SS-OCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rotating Scheimpflug camera (RSC)
Number of subjects: 100
Study: 35606889

Group type: EXPERIMENTAL
Intervention: Microbiome-targeted dietary intervention for 6 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Microbiome-targeted dietary intervention
Number of subjects: 9
Study: 35607935

Group type: EXPERIMENTAL
Intervention: Cochlear implantation (Cohort 1 and Cohort 2)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Hearing aids (Cohort 3)
Number of subjects: 204
Study: 35607978

Group type: EXPERIMENTAL
Intervention: GSK2556286
Number of subjects: 0
Study: 35607994

Group type: EXPERIMENTAL
Intervention: Aspirin treatment in 2015
Number of subjects: 4611

Group type: EXPERIMENTAL
Intervention: Invasive strategy in 2011
Number of subjects: 4611

Group type: EXPERIMENTAL
Intervention: Invasive strategy in 2015
Number of subjects: 4611

Group type: EXPERIMENTAL
Intervention: In-hospital mortality in men from 2006 to 2015
Number of subjects: 4611

Group type: EXPERIMENTAL
Intervention: In-hospital mortality in women from 2006 to 2015
Number of subjects: 4611
Study: 35608080

Group type: EXPERIMENTAL
Intervention: Video telehealth
Number of subjects: 0

Group type: COMPARATOR
Intervention: No video telehealth
Number of subjects: 0
Study: 35608216

Group type: EXPERIMENTAL
Intervention: Immediate surgical management
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Open repairs
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Use of mesh in repairs
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: 90-day mortality rate
Number of subjects: 272
Study: 35608264

Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (wb-MRI) and serological follow-up
Number of subjects: 96
Study: 35608376

Group type: EXPERIMENTAL
Intervention: 4-week exercise and nutrition prehabilitation program (blood flow restriction exercise and sports nutrition supplement)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual preoperative care (control group)
Number of subjects: 21
Study: 35608445

Group type: EXPERIMENTAL
Intervention: 2-(3-{1-carboxy-5-[(6-
Number of subjects: 0
Study: 35608696

Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV) for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume-control ventilation (VCV) for 30 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flow-controlled ventilation (FCV)
Number of subjects: 0
Study: 35608793

Group type: EXPERIMENTAL
Intervention: Apathetic participants (30)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-apathetic participants (26)
Number of subjects: 56
Study: 35608822

Group type: EXPERIMENTAL
Intervention: Selinexor (40 mg on days 1, 8, 15) and Ibrutinib (420 mg daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Selinexor and Ibrutinib combination
Number of subjects: 34
Study: 35608877

Group type: EXPERIMENTAL
Intervention: Time to surgical source control
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: SOFA score greater than 2
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Age greater than 60 years
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Generalized peritonitis
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Laparotomy surgery
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Time to imaging, antibiotic therapy, and surgery
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 205
Study: 35608887

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 29
Study: 35609087

Group type: EXPERIMENTAL
Intervention: Simplified Geneva score with objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Simplified Geneva score without objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Original Geneva score with objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Original Geneva score without objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Padua score with objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Padua score without objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: IMPROVE score with objective mobility measures
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: IMPROVE score without objective mobility measures
Number of subjects: 1350
Study: 35609221

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care
Number of subjects: 526

Group type: COMPARATOR
Intervention: Serial care
Number of subjects: 526
Study: 35609312

Group type: EXPERIMENTAL
Intervention: Lower-leg injury
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Number of subjects: 1204
Study: 35609637

Group type: EXPERIMENTAL
Intervention: Transition to comfort care only in AGU
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Frailty trajectory in patients living with dementia or not
Number of subjects: 177

Group type: COMPARATOR
Intervention: Frailty among people living without dementia
Number of subjects: 177
Study: 35609913

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg IV on day 0, followed by 100 mg IV daily for 10 days) plus standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard treatment
Number of subjects: 0
Study: 35609996

Group type: EXPERIMENTAL
Intervention: Potassium Chloride (KCl) supplementation
Number of subjects: 191
Study: 35610084

Group type: EXPERIMENTAL
Intervention: 0-0.5 cups/day of fruits and berries
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: 150-300 g fish/week
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: <1 cup/week legumes
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: 0-0.5 servings of full-fat dairy/day
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: 0.5-1 servings of full-fat dairy/day
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: Younger age (<45 years)
Number of subjects: 2816

Group type: EXPERIMENTAL
Intervention: Low/medium levels of waist circumference
Number of subjects: 2816
Study: 35610089

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study: 35610144

Group type: EXPERIMENTAL
Intervention: Nutritional status assessed using GNRI < 91
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Nutritional status assessed using higher CONUT group
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Nutritional status assessed using PNI < 48 points
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Thyroid hormones (TSH, fT3, fT4) as continuous variables
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Modified Frailty Index-11
Number of subjects: 252
Study: 35610195

Group type: EXPERIMENTAL
Intervention: Urine microscopy score (UMS) ≥1 at 6 hours after SICU admission
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Urine microscopy score (UMS) ≥1 at 12 hours after SICU admission
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Urine microscopy score (UMS) ≥3 at 6 hours after SICU admission
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Urine microscopy score (UMS) =1-2 at 6 hours after SICU admission
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Urine microscopy score (UMS) ≥1
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Higher UMS (≥3, 1-2 and 0)
Number of subjects: 661
Study: 35610260

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1512

Group type: COMPARATOR
Intervention: AIS-low patients
Number of subjects: 1512
Study: 35610336

Group type: EXPERIMENTAL
Intervention: Humanoid avatars representing adolescent body size and shape changes over five decades.
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Three-dimensional whole-body scan data collection.
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Alignment of biometric and visual information.
Number of subjects: 223
Study: 35610367

Group type: EXPERIMENTAL
Intervention: Resection/local ablative therapy (LAT)
Number of subjects: 906

Group type: COMPARATOR
Intervention: Systemic therapy only
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Resection/LAT
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Upfront resectability
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Conversion rates
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Resection/LAT rates
Number of subjects: 906
Study: 35610473

Group type: EXPERIMENTAL
Intervention: Men with COPD
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Women with COPD
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Men with COPD (pulmorbidome)
Number of subjects: 2575

Group type: EXPERIMENTAL
Intervention: Women with COPD (pulmorbidome)
Number of subjects: 2575
Study: 35610522

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) followed by a 3-year lifestyle-based weight maintenance (WM) intervention
Number of subjects: 2223

Group type: EXPERIMENTAL
Intervention: 3-year lifestyle-based weight maintenance (WM) intervention
Number of subjects: 2223

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) followed by a lifestyle intervention
Number of subjects: 2223
Study: 35610543

Group type: EXPERIMENTAL
Intervention: Vertebral body tethering (VBT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Posterior spinal fusion (PSF)
Number of subjects: 26
Study: 35610609

Group type: EXPERIMENTAL
Intervention: Online palliative rehabilitation blended learning program (EMBRACE)
Number of subjects: 22
Study: 35610739

Group type: EXPERIMENTAL
Intervention: 14 Fr percutaneous catheter (P-CAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 28-32 Fr open chest tube
Number of subjects: 0
Study: 35611270

Group type: EXPERIMENTAL
Intervention: Laser interstitial thermal therapy (LITT)
Number of subjects: 89
Study: 35611354

Group type: EXPERIMENTAL
Intervention: Positive Deviance/Hearth-Interactive Voice Calling program
Number of subjects: 0
Study: 35611499

Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy (10 mg/kg every 2 weeks)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg for 4 doses, followed by durvalumab 20 mg/kg Q4W)
Number of subjects: 240
Study: 35611697

Group type: EXPERIMENTAL
Intervention: KTE-X19 (brexucabtagene autoleucel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study: 35611878

Group type: EXPERIMENTAL
Intervention: Re-testing with coeliac disease autoantibodies
Number of subjects: 599
Study: 35612394

Group type: EXPERIMENTAL
Intervention: Combined Nurse Care Manager and Community Health Worker training curriculum
Number of subjects: 0
Study: 35612403

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35612465

Group type: EXPERIMENTAL
Intervention: Patient-Facing Mobile Teledermatology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35612877

Group type: EXPERIMENTAL
Intervention: Mindhelper, an online national youth mental health promotion service
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Mindhelper
Number of subjects: 560
Study: 35612881

Group type: EXPERIMENTAL
Intervention: Dyadic intervention with joint health education counseling and a single individual session (Sister to Sister or Focus on the Future) with a gender-matched health educator.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dyadic intervention with joint debriefing session to discuss relationship dynamics, condom negotiation, etc.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 100
Study: 35612893

Group type: EXPERIMENTAL
Intervention: VPPRN cohort (self-reported data)
Number of subjects: 549

Group type: COMPARATOR
Intervention: VCRC cohort (physician-reported data)
Number of subjects: 549
Study: 35612990

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 666

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 666
Study: 35613338

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA) for diabetes distress
Number of subjects: 178

Group type: COMPARATOR
Intervention: Questionnaire-based assessment of diabetes distress
Number of subjects: 178
Study: 35613364

Group type: EXPERIMENTAL
Intervention: Combined Abelmoschus manihot and Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35613417

Group type: EXPERIMENTAL
Intervention: Consumer-grade wearables (smartwatches)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Risk score based on physiological measurements
Number of subjects: 40
Study: 35613760

Group type: EXPERIMENTAL
Intervention: In-hospital management for TIA and stroke patients
Number of subjects: 10000
Study: 35613775

Group type: EXPERIMENTAL
Intervention: Risk prediction function incorporating modifiable lifestyle factors
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Blood tests on Oral Glucose Tolerance Test (OGTT) and haemoglobin A1C (HbA1c)
Number of subjects: 1014
Study: 35613803

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) imaging of the larynx during non-invasive ventilation (NIV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) imaging of the larynx during mechanical insufflation-exsufflation (MI-E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Simultaneous TFL and laryngeal US imaging
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Airflow and pressure signals during NIV and MI-E
Number of subjects: 30
Study: 35613814

Group type: EXPERIMENTAL
Intervention: Percutaneous transuterine fetal cerebral embolisation using coils to embolise the draining venous malformation.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Percutaneous transuterine fetal cerebral embolisation.
Number of subjects: 20
Study: 35614039

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 35614475

Group type: EXPERIMENTAL
Intervention: NMF component 1 (highest exposure to several synthetic pesticides)
Number of subjects: 33013
Study: 35614481

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CFO) worn for 7 weeks
Number of subjects: 20
Study: 35614978

Group type: EXPERIMENTAL
Intervention: 2 g/day of grape polyphenol extract
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 35615559

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 305
Study: 35615627

Group type: EXPERIMENTAL
Intervention: Structured active play intervention (combined in-hospital and home-based program, 45-min sessions three times weekly)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care (including physiotherapy)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Structured active play intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study: 35615688

Group type: EXPERIMENTAL
Intervention: Quercetin (QUE)
Number of subjects: 0
Study: 35615718

Group type: EXPERIMENTAL
Intervention: rATG (rabbit antithymocyte globulin) administered intravenously at a dose of 0.8-1.0 mg/kg daily (cumulative dose of 150-200 mg)
Number of subjects: 7
Study: 35615755

Group type: EXPERIMENTAL
Intervention: ActivPAL3™ activity monitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SENS motion® activity monitor
Number of subjects: 0
Study: 35615875

Group type: EXPERIMENTAL
Intervention: Primary retrograde strategy
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Successful primary retrograde cases
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Unsuccessful primary retrograde cases
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Presence of interventional collaterals
Number of subjects: 1329
Study: 35616437

Group type: EXPERIMENTAL
Intervention: Repetitive task practice using a combination of robot-assisted therapy and functional arm use in real-world tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 0
Study: 35616848

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1094
Study: 35617162

Group type: EXPERIMENTAL
Intervention: Mild Takotsubo cardiomyopathy (TTC)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Severe Takotsubo cardiomyopathy (TTC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Non-Takotsubo cardiomyopathy (non-TTC)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Wall motion score index
Number of subjects: 136

Group type: COMPARATOR
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Barthel's score
Number of subjects: 136

Group type: COMPARATOR
Intervention: Karnofsky score
Number of subjects: 136
Study: 35617288

Group type: EXPERIMENTAL
Intervention: Long-term sequelae assessment (physical, neurological, or sensory)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term post-traumatic stress assessment in parents
Number of subjects: 100
Study: 35617367

Group type: EXPERIMENTAL
Intervention: TsG10-TsG10-*bt assay
Number of subjects: 29

Group type: COMPARATOR
Intervention: Polyclonal based assay
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: New recombinant monoclonal antibody-based Ts Ag detection immunoassay
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: TsG10 assay
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Detection of Ts antigen in urine
Number of subjects: 29
Study: 35617646

Group type: EXPERIMENTAL
Intervention: Circulating tumor cell (CTC) enumeration and expression of HLA I and PD-L1
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CTC enumeration trajectory in the highest quartile (> 0.12 CTCs/mL annually)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CTC enumeration and HP ratio changes over time
Number of subjects: 104
Study: 35617923

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35617978

Group type: EXPERIMENTAL
Intervention: Radiation segmentectomy
Number of subjects: 29
Study: 35618285

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) intravenously every 21 days
Number of subjects: 29
Study: 35618347

Group type: EXPERIMENTAL
Intervention: Shift work
Number of subjects: 412
Study: 35618353

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35618441

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (5, 10, or 20 mg/kg every other week for 6 months, then 20 mg/kg qow)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa
Number of subjects: 24
Study: 35618839

Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with low-dose cyclophosphamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: All-comer cohorts (control)
Number of subjects: 30
Study: 35619114

Group type: EXPERIMENTAL
Intervention: Ultra-processed food intake during pregnancy
Number of subjects: 458
Study: 35619134

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Ferritin levels (two-fold increase)
Number of subjects: 1888
Study: 35619189

Group type: EXPERIMENTAL
Intervention: Nebulized haMSC-Exos (2.0 × 10^6 exosomes daily for 5 days)
Number of subjects: 7